Viral Related Tools against SARS-CoV-2

At the end of 2019, a new disease appeared and spread all over the world, the COVID-19, produced by the coronavirus SARS-CoV-2. As a consequence of this worldwide health crisis, the scientific community began to redirect their knowledge and resources to fight against it. Here we summarize the recent...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2020-10, Vol.12 (10), p.1172
Main Authors: Fernandez-Garcia, Laura, Pacios, Olga, González-Bardanca, Mónica, Blasco, Lucia, Bleriot, Inés, Ambroa, Antón, López, María, Bou, German, Tomás, Maria
Format: Article
Language:English
Subjects:
Adenoviruses
Antibodies
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
Antigens
Antiviral Agents - therapeutic use
Asymptomatic
Bacteria
Bacterial infections
Bacteriophages
Betacoronavirus - isolation & purification
Clinical trials
Coronavirus Infections - therapy
Coronavirus Infections - virology
Coronaviruses
COVID-19
COVID-19 vaccines
CRISPR
CRISPR-Cas Systems
Ebola virus
Hepatitis
HIV
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Influenza
Medical research
Pandemics
Phage Therapy
Phages
Pneumonia, Viral - therapy
Pneumonia, Viral - virology
prevention
Proteins
Review
RNA polymerase
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Tropical diseases
Vectors (Biology)
Viral diseases
Viral infections
Viral Vaccines - immunology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At the end of 2019, a new disease appeared and spread all over the world, the COVID-19, produced by the coronavirus SARS-CoV-2. As a consequence of this worldwide health crisis, the scientific community began to redirect their knowledge and resources to fight against it. Here we summarize the recent research on viruses employed as therapy and diagnostic of COVID-19: (i) viral-vector vaccines both in clinical trials and pre-clinical phases; (ii) the use of bacteriophages to find antibodies specific to this virus and some studies of how to use the bacteriophages themselves as a treatment against viral diseases; and finally, (iii) the use of CRISPR-Cas technology both to obtain a fast precise diagnose of the patient and also the possible use of this technology as a cure.
ISSN:1999-4915
1999-4915
DOI:10.3390/v12101172